{"name":"Antengene Biologics Limited","slug":"antengene-biologics-limited","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"ATG-031","genericName":"ATG-031","slug":"atg-031","indication":"Other","status":"phase_1"},{"name":"ATG-022","genericName":"ATG-022","slug":"atg-022","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ATG-031","genericName":"ATG-031","slug":"atg-031","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ATG-022","genericName":"ATG-022","slug":"atg-022","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxNM1QxOV9KUG9ocjNrdmRUeENSYjBKOFJNNUlUd0dEdy1HdkRycm80dS00X3Q5SDdDMXlGMXZwMlJlaHBJOUhldFJJd2ZaYnNsazhUQnlpZVFJVTZYQkxxNU9pX2ZaZlQ3QklvQ1NBZXpYcHM0SE1qNW1OWnlKSlFLTDN0UXZWdlpIWDdTOVd4UQ?oc=5","date":"2026-03-04","type":"deal","source":"The Pharma Letter","summary":"UCB inks license agreement with Antengene - The Pharma Letter","headline":"UCB inks license agreement with Antengene","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE90bDZZXzhMOHFEWFdsZFVYZFVqLXQ2YzVfdEY5aGFRamlaZEVEUHk2LWxCOWc0OG9qQVJlSENIYXZJYWR1S2pqdVYzeThKRkRvTW1NZF9kQk5FYWl2LTcyamZnbUdfTVZQSkFYamxn0gFyQVVfeXFMUDhKa1B0TktQSkl0cnZpbkFZdmhnNkRXVnBzSHhUTUNNVk5FVDJma3l0TWVobkNuNWxuRjdwallMTHppb0lDbzZWQkZRbEgxeXFuSG9hZmZEUm1GZFYtR09QRUN0X3hpZmgzY2lOcVB5amRB?oc=5","date":"2026-03-04","type":"deal","source":"koreabiomed.com","summary":"Boryung adds Xpovio to blood cancer portfolio under Antengene license deal - koreabiomed.com","headline":"Boryung adds Xpovio to blood cancer portfolio under Antengene license deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQdDJqZko5NS1lZWlQMndhQWpkQ2tYekpoNHRXV3k4dDdLUHB4Yy12TkNwMzhQaDdSLTRLdWJpbEhXbm5tMTE5SWstVGppSkI1aWlTMEJOV1pNWVA4d0dtaE0wSHJKd1lnSmo0WXhHSTlzMUc4ZjcwTVVYOVBXckRyMGZiQW1lMHl2SDVvbFRkbVIzQXpXeng3UnZoZC1ZNnNP?oc=5","date":"2026-03-04","type":"deal","source":"BioWorld News","summary":"UCB inks $1.1B deal for Antengene’s autoimmune bispecific TCE - BioWorld News","headline":"UCB inks $1.1B deal for Antengene’s autoimmune bispecific TCE","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwJBVV95cUxPNF9YNzZfNFdvblZJeV9YWWViZVBLY1pxZlZ6LVZUVktXaGtwaXluejduNnVZNFhLay1lZmlXWnV3THJMNVMxNGpQczZnNTNhVEJlSk05dGxNeDlJV0VVR2l3bkVtZkFvZE5RLWE5VEQwMFBSSm5oeVcxMVBlTnVEMXZHTHRsX3ZfQkdMVkZEMXNxUi1CMm00bm5feER1aHZPXzZOeVY4cXpIeVZWR3cxUWtMQUpOWmpjNWZCdDJaUHdmYm1ROFZCQkcyNDA2WlY0bGN1R2hnOGNNQndvNzJQQmFBV2Nqb0RjOWYzbm1IWlVQRXdtV1JRQ1FGSXhwTnZXX0xTbi1jNA?oc=5","date":"2026-03-03","type":"deal","source":"PR Newswire","summary":"Antengene and UCB Enter Global License Agreement for ATG-201, a CD19/CD3 Bispecific T-Cell Engager for Autoimmune Diseases - PR Newswire","headline":"Antengene and UCB Enter Global License Agreement for ATG-201, a CD19/CD3 Bispecific T-Cell Engager for Autoimmune Diseas","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxPVk5DSjdXTGhMelpJZ09wejJVemhyRGh5U2ZzTFVOb0J4dGlCZjV6WlI1U2czS21RTjJsR1I3WFI1MzhUNjZYYzNMQ0JJeVpPR2UtQmpYSWl6Xzg3dlpVVnQ0S0pfaEp3Vy01eXpOZENfMXBia3Q1b0pqdzlJQWg0dERIN0haajZYSndKNFJRWWpTQ2UxX0dxTGNlQjdjUzZkaV9qenpLX2JtUWdXRk1acEVGMWZQWlc2SGdKLUp6dzJ0dS1xNnN0ZmE4UmFsSjhRTHJCcEMxaEg5U1VjNjBFRjlIQU5WSnc?oc=5","date":"2025-05-21","type":"deal","source":"BioPharma APAC","summary":"Antengene and MSD Enter Global Clinical Collaboration to Evaluate ATG-022 and KEYTRUDA® Combo in Solid Tumors - BioPharma APAC","headline":"Antengene and MSD Enter Global Clinical Collaboration to Evaluate ATG-022 and KEYTRUDA® Combo in Solid Tumors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxOWk51dEJ3MjZ4cjNrOV9CSVJKZUJieWRYY0YyNG16TFJIaXVvVk5BOHE0aXFLOG9PNUNDWUNxSEdwOFZyZmNsc2JRUnJ5a1pfbkJmR3ktcHEwUTZkV1p3eVhTNXR4U1NOcVRXVzJIMi1sRlFNYUl3QzVXT3dTS3NLa3YyVFpJWm1TVHVMeTdkMTNWWFlXVnBZb0NVbXBhTm5kU3QzR3JsQTJ2ZUxsR1JyWVhoanNnOHFlTWdDby1KTlY4aFVOaE5rcg?oc=5","date":"2024-11-29","type":"pipeline","source":"BioPharma APAC","summary":"China’s 2024 National Reimbursement Drug List Expands Access to Cutting-Edge Therapies - BioPharma APAC","headline":"China’s 2024 National Reimbursement Drug List Expands Access to Cutting-Edge Therapies","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}